Industry Outlook
The mobile cancer screening devices market is expected to highlighting positive growth at a compounded annual growth rate (CAGR) of 5.6% during the forecast period from 2019 to 2027. The mobile cancer screening devices are well equipped with efficient ergonomic features and are less expensive in comparison to conventional screening devices. Rising prevalence of cancer worldwide and increasing demand for portable screening devices among oncologist consolidates the market growth for mobile cancer screening devices.
Market Synopsis
Get a sample copy for more information
"Most common cancer type in women worldwide and burgeoning requirement of early screening to reduce the mortality rate drive the breast cancer market growth"
According to the American Institute for Cancer Research, breast cancer is the most common type of cancer occurring in women population worldwide. In 2018, approximately 2,088,849 cases were diagnosed for breast cancer throughout the globe. Medical device companies are actively engaged in developing mobile cancer screening devices with excellent ergonomic features, low cost and quick turnaround time required in early screening to curb the high mortality rate associated with the disease. As per the research findings of World Health Organization (WHO), cervical cancer is the fourth most occurring cancer in the female population, in 2018 around 570,000 new cases were reported worldwide. Oncologists are recommending the need for portable colposcopes to perform effective diagnosis of cervical cancer.
Get a sample copy for more information
"Increasing public health awareness pertaining to cancer and low cost burden associated with cancer treatment increases the demand for specialty clinics"
Specialty clinics are spearheading the end user segment for mobile cancer screening devices market. The chief parameters increasing its demand are rising public health awareness pertaining to cancer and reduced cost burden associated with cancer treatment. Hospitals will be registering impressive growth during the forecast period owing to the proactive role adopted by government healthcare agencies to fight cancer by providing huge financial aid to promote early cancer diagnosis. Presence of huge patient pool suffering with cancer can be enrolled in clinical trial studies to check the accuracy and precise interpretation & scanning of novel mobile cancer screening device under investigation.
Get a sample copy for more information
"Rising prevalence of cancer and presence of pioneering IT Healthcare firms engaged in development of mobile cancer screening devices drive market growth in North America"
North America is responsible for 34.5% market share and is the leading regional segment for global mobile screening devices market. The major constituents influencing its proactive market growth are rising prevalence of cancer. The statistics brought forward by American Cancer Society (ACS) in 2019, approximately 1,762,450 new cancer cases have been reported. Presence of pioneering IT-healthcare firms actively engaged in development of mobile cancer screening devices further strengthens the market growth in the region. Europe is accountable for 29.5% on account of high mortality rate associated with advanced stage cancer. According to the research citing provided by World Health Organization (WHO), annually 1.9 million people die due to cancer in Europe due to delayed diagnosis and medical intervention. Asia Pacific holds 16% market share and will be growing at a rapid pace in the near future owing to emerging startup companies in collaboration with major players to develop mobile cancer screening devices and significant rise in number of specialty clinics engaged in cancer treatment.
Historical & Forecast Period
This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
The market is segmented by application, end user and by geography.
| ATTRIBUTE |
DETAILS |
| Research Period |
2017-2027 |
| Base Year |
2018 |
| Forecast Period |
2019-2027 |
| Historical Year |
2017 |
| Unit |
USD Million |
| Segmentation |
By Application (2017–2027; US$ Mn)
• Cervical Cancer
• Breast Cancer
• Oral Cancer
• Others
|
|
By End User (2017–2027; US$ Mn)
• Home Care Settings
• Specialty Clinics
• Hospital
|
|
Geography Segment (2017–2027; US$ Mn)
• North America (U.S., Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (China, Japan, Rest of APAC)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of Middle East and Africa)
|
Medical device companies and IT Healthcare firms engaged in the development of mobile cancer screening devices are AbDent, Inc., Apteryx, Inc., Breastlight, Braster S.A., Bremed Ltd., Forward Science, MobileODT Ltd., Niramai Health Analytix, TruScreen and UE LifeSciences.
Key questions answered in this report
- Which IT healthcare companies are developing mobile cancer screening devices?
- What are the latest merger, acquisition and collaboration happening in the mobile cancer screening devices market?
- What is the prevalence rate and mortality rate of different types of malignant cancers?
- What factors increases the popularity of specialty clinics?
- What is the market performance of mobile cancer screening devices in Europe and North America?
